Tumor immune checkpoints (TICs) such as PDCD1 (PD-1), CTLA4, IDO1, and CD40 are critical regulators of immune responses and have emerged as promising therapeutic targets in cancer immunotherapy (18). This evidence concerns the gene CD40 and cancer.